Dicla-cocci 2.5 mg/ml Oral Suspension for Cattle and Sheep

Calves:
In certain cases, only a transient reduction of oocyst shedding may be achieved.
If there is no recent and confirmed history of clinical coccidiosis, the presence of the
disease in the flock or herd should be confirmed by faecal sampling prior to
treatment.
The preferred timing of treatment is directed by the known epidemiology of Eimeria
spp. with treatment being most effective during the pre-patent phase of the infection
before clinical signs occur.
Coccidiosis is an indicator of insufficient hygiene in the flock/pen. It is recommended
to improve hygiene and to treat all calves in a pen and all lambs in a group. This will
contribute to reduce the infection pressure and assure a better epidemiological
control of the coccidiosis infection.
Repeated use for an extended period, particularly when using the same class of
substances, increases the risk of resistance development. The decision to use the
product should be based on confirmation of the coccidian species and burden, or of
the risk of infection based on its epidemiological features, for each herd/flock.
Unnecessary use of antiprotozoals or use deviating from the instructions given in the
SPC may increase the resistance selection pressure and lead to reduced efficacy.
Cross-resistance between toltrazuril and diclazuril is possible and should be
investigated. Use of diclazuril should be carefully considered when susceptibility
testing has shown resistance to triazine-derivates because its effectiveness may be
reduced.
It is recommended to further investigate cases of suspected resistance, using an
appropriate diagnostic method (e.g. faecal oocyst count reduction test). Confirmed
resistance should be reported to the marketing authorisation holder or to the competent
authorities. If resistance is present, it should be considered to use an antiprotozoal
from another class/with a different mechanism of action.
Therapy should be based on epidemiological information and knowledge of
susceptibility of the target pathogens at farm level, or at local/regional level.
Use of the product should be in accordance with official, national and regional
antimicrobial policies.
To alter the course of an established clinical coccidial infection, in individual animals
already showing signs of diarrhoea, additional supportive therapy is required.
AN: 01331/2025 & 01375/2025

Special precautions for safe use in the target species:
This veterinary medicinal product should only be used in a restricted number of
animals at high risk of infection, i.e. animals kept in the same restricted,
contaminated environment.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Esters of parahydroxybenzoic acid may cause allergic reactions (possibly delayed).
People with known hypersensitivity to parabens should administer the veterinary
medicinal product with caution.
Wash hands after administration of the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.